Views & Analysis | Perspectives on pharma industry issues

Market Access

JPM 2026: What it revealed about biotech’s new reality

JPM 2026 signalled genuine recovery – but not the kind the industry has historically celebrated.

Sales & Marketing

Pharma’s search loophole is a preview of what comes next

PPC ads often contain so little text that they avoid direct claims. Many consist only of a brand name, a link, and limited copy.

Digital

Sponsored

Legacy data into living scientific memory

The pharmaceutical industry is racing to turn its data into scientific intelligence with AI. Now it’s possible to connect your data and tool ecosystem

R&D

Clinical trials, various research areas, concept

Clinical Trials Round-Up – Jan to Feb 2026

Read how Jan-Feb '26 offered a revealing cross-section of how R&D is evolving across therapy areas.

R&D

pharmaphorum podcast Episode 248, Andrew McKinnon, Medable

AI in clinical development & ‘white space’, with Andrew McKi...

Andrew McKinnon, senior vice president and executive general manager at Medable, discussesleveraging AI to transform & accelerate clinical development

Sales & Marketing

Gen Z: The untapped audience

The pandemic had a huge impact on where and how people seek out medical information and advice, with a large percentage of people becoming far less likely to follow a more traditional route

Sales & Marketing

Life sciences arbitration trends

The life sciences industry is seeing huge growth right now.

Market Access

Reuters Pharma Barcelona 2023 - Day 3

Day Three arrives and Reuters Pharma 2023 comes to a close – but not before Boehringer Ingelheim talks to us about accelerating time-to-patient and an expert panel discusses empowering a wh

Sales & Marketing

Pharma’s search loophole is a preview of what comes next

PPC ads often contain so little text that they avoid direct claims. Many consist only of a brand name, a link, and limited copy.

Sales & Marketing

virtual electronic medical record interface

Sponsored

5 forces reshaping pharma commercialisation in 2026

As infrastructure bottlenecks ease and regulatory frameworks mature, pharma's AI adoption is shifting from proof-of-concept to production-grade deployment

Digital

Sponsored

Legacy data into living scientific memory

The pharmaceutical industry is racing to turn its data into scientific intelligence with AI. Now it’s possible to connect your data and tool ecosystem

Digital

Sponsored

Accelerating the content lifecycle: A 7-step guide for AI in...

By integrating AI agents into medical, legal, and regulatory (MLR) processes, organisations can transform content lifecycle management.

Market Access

JPM 2026: What it revealed about biotech’s new reality

JPM 2026 signalled genuine recovery – but not the kind the industry has historically celebrated.

Market Access

What rare disease commercialisation in Europe teaches us - a...

Rare disease launches are the ultimate stress test for European commercialisation.

Oncology

Sponsored

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

Oncology